PL1942108T3 - Związek zawierający grupę zasadową i jego zastosowanie - Google Patents
Związek zawierający grupę zasadową i jego zastosowanieInfo
- Publication number
- PL1942108T3 PL1942108T3 PL06822530T PL06822530T PL1942108T3 PL 1942108 T3 PL1942108 T3 PL 1942108T3 PL 06822530 T PL06822530 T PL 06822530T PL 06822530 T PL06822530 T PL 06822530T PL 1942108 T3 PL1942108 T3 PL 1942108T3
- Authority
- PL
- Poland
- Prior art keywords
- compound containing
- basic group
- containing basic
- group
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005313796 | 2005-10-28 | ||
| EP06822530.9A EP1942108B1 (en) | 2005-10-28 | 2006-10-27 | Compound containing basic group and use thereof |
| PCT/JP2006/321569 WO2007049771A1 (ja) | 2005-10-28 | 2006-10-27 | 塩基性基を含有する化合物およびその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1942108T3 true PL1942108T3 (pl) | 2014-03-31 |
Family
ID=37967879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06822530T PL1942108T3 (pl) | 2005-10-28 | 2006-10-27 | Związek zawierający grupę zasadową i jego zastosowanie |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8318931B2 (pl) |
| EP (2) | EP1942108B1 (pl) |
| JP (2) | JP5251127B2 (pl) |
| DK (1) | DK1942108T3 (pl) |
| ES (1) | ES2427989T3 (pl) |
| PL (1) | PL1942108T3 (pl) |
| PT (1) | PT1942108E (pl) |
| WO (1) | WO2007049771A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2055705A4 (en) * | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF |
| EP2161256A1 (en) * | 2008-09-08 | 2010-03-10 | Atomic Energy Council - Institute of Nuclear Energy Research | Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| TW201103540A (en) * | 2009-06-16 | 2011-02-01 | Ono Pharmaceutical Co | Compound having spiro-linked cyclic group and uses thereof |
| TWI633087B (zh) * | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US10144747B2 (en) | 2013-07-09 | 2018-12-04 | Lehigh University | Reagents and methods for fluorinating a substrate |
| NO3074400T3 (pl) | 2013-11-26 | 2018-04-14 | ||
| EP3122751B1 (en) | 2014-03-26 | 2019-10-30 | F.Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| MA39792B1 (fr) | 2014-03-26 | 2019-12-31 | Hoffmann La Roche | Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa) |
| US9655816B2 (en) | 2014-04-09 | 2017-05-23 | Kuraray Co., Ltd. | Liquid packaging container |
| TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
| JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体モジュレーターの固体形態 |
| US9573952B2 (en) * | 2014-09-16 | 2017-02-21 | Gilead Sciences, Inc. | Methods of preparing toll-like receptor modulators |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| MX387736B (es) | 2015-09-04 | 2025-03-18 | Hoffmann La Roche | Derivados de fenoximetilo. |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
| PE20180451A1 (es) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
| MA49879A (fr) | 2017-03-16 | 2020-06-24 | Hoffmann La Roche | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| CN109761979B (zh) * | 2019-03-19 | 2020-04-17 | 中国医学科学院医药生物技术研究所 | 一种含3-三氟甲基-苯基取代基的二氮杂螺环类衍生物及其制备方法和应用 |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
| EP3769761A1 (en) * | 2019-07-26 | 2021-01-27 | Charité - Universitätsmedizin Berlin | Cxcr4 antagonists for treatment of cardiovascular conditions |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (pl) | 1956-03-21 | 1900-01-01 | ||
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| GB8334626D0 (en) | 1983-12-30 | 1984-02-08 | Exxon Research Engineering Co | Zeolite coated substrates |
| US6686353B1 (en) * | 1996-05-20 | 2004-02-03 | Teijin Intellectual Property Center Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| AU5803398A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| US6172061B1 (en) | 1997-12-19 | 2001-01-09 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| DE19801265C1 (de) | 1998-01-15 | 1999-08-12 | Deutsches Krebsforsch | Inhibierung von CD95-unabhängiger Apoptose bei AIDS |
| EP1052992A1 (en) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| CA2329821A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| WO2000004003A1 (en) | 1998-07-14 | 2000-01-27 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP2002521441A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | Ccr5モジュレーターとしてのプロペンアミド |
| CA2338697A1 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
| HUP0102752A3 (en) | 1998-07-28 | 2002-11-28 | Smithkline Beecham Corp | Substituted anilide compounds |
| AU5301599A (en) | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
| WO2000021916A1 (fr) | 1998-10-15 | 2000-04-20 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives d'amine |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027800A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| PT1131291E (pt) | 1998-11-17 | 2005-01-31 | Hoffmann La Roche | Antagonistas iii do receptor 4-aroil-piperidin-ccr-3 |
| KR20010081034A (ko) | 1998-11-20 | 2001-08-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 피페리딘 씨씨알-3 수용체 길항제 |
| JP3593037B2 (ja) | 1998-11-20 | 2004-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | ピロリジン誘導体ccr−3受容体アンタゴニスト |
| CN1149214C (zh) | 1998-12-04 | 2004-05-12 | 东丽株式会社 | 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂 |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2347912A1 (en) | 1998-12-18 | 2000-06-22 | Soo S. Ko | Heterocyclic piperidines as modulators of chemokine receptor activity |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ATE302005T1 (de) | 1998-12-18 | 2005-09-15 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2056700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| AU1690100A (en) | 1998-12-21 | 2000-07-12 | Takeda Chemical Industries Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| ATE264100T1 (de) | 1998-12-30 | 2004-04-15 | Smithkline Beecham Corp | Zusammensetzung und verfahren |
| WO2000042045A2 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Functionalized heterocycles as chemokine receptor modulators |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000042852A1 (en) | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Compounds and methods |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
| AU3389300A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AU3386500A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| US6303593B1 (en) | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| US6489354B1 (en) | 1999-03-02 | 2002-12-03 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| ATE270547T1 (de) | 1999-03-10 | 2004-07-15 | Smithkline Beecham Corp | Substituierte benzo(1,2-b:5,4-b')dipyran-4-amine als ccr5 modulatoren |
| WO2000053600A1 (en) | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| EE200100502A (et) | 1999-03-26 | 2002-12-16 | Astrazeneca Ab | Ühendid |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| AU4143300A (en) | 1999-04-28 | 2000-11-17 | Takeda Chemical Industries Ltd. | Cyclic amide compounds, process for the preparation of the same and uses thereof |
| WO2000066112A1 (en) | 1999-05-03 | 2000-11-09 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| CZ301161B6 (cs) | 1999-05-04 | 2009-11-18 | Schering Corporation | Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující |
| TR200103214T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| PT1175224E (pt) | 1999-05-04 | 2005-07-29 | Schering Corp | Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5 |
| US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
| ES2250132T3 (es) | 1999-05-18 | 2006-04-16 | Teijin Limited | Remedios preventivos para enfermedades asociadas a quimioquinas. |
| EP1181310A1 (en) | 1999-05-27 | 2002-02-27 | Celltek Biotechnologies Inc. | Chemokine receptor ccr3 antagonists |
| US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
| WO2001009088A1 (en) | 1999-07-28 | 2001-02-08 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| US6608227B1 (en) * | 1999-10-15 | 2003-08-19 | Bristol-Myers Squibb Pharma | Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| US20020173524A1 (en) | 2000-10-11 | 2002-11-21 | Tularik Inc. | Modulation of CCR4 function |
| WO2002094261A1 (fr) | 2001-05-24 | 2002-11-28 | Kureha Chemical Industry Company, Limited | Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote |
| US6693134B2 (en) | 2001-05-29 | 2004-02-17 | Chemokine Therapeutics Corporation | Bicyclic aromatic chemokine receptor ligands |
| JP2002371042A (ja) | 2001-06-12 | 2002-12-26 | Takeda Chem Ind Ltd | ジアミン化合物、その製造法および用途 |
| WO2003029218A1 (en) | 2001-09-28 | 2003-04-10 | Kureha Chemical Industry Company, Limited | Novel nitrogenous compound and use thereof |
| EP1488239A2 (en) | 2002-03-20 | 2004-12-22 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| ES2403932T3 (es) | 2002-08-27 | 2013-05-22 | Biokine Therapeutics Ltd. | Antagonista de CXCR4 y uso del mismo |
| DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
| JP4391123B2 (ja) | 2002-10-24 | 2009-12-24 | 株式会社オーファンリンク | 新規cxcr4アンタゴニスト |
| AU2003284984B2 (en) * | 2002-10-30 | 2008-10-23 | Merck Sharp & Dohme Corp. | Gamma-aminoamide modulators of chemokine receptor activity |
| US20040132642A1 (en) | 2002-11-12 | 2004-07-08 | Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services | Methods of inhibiting metastasis or growth of a tumor cell |
| WO2004052862A1 (ja) | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| WO2004054603A2 (en) | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Use of beta-defensins for treating hiv infections |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| CA2517077C (en) | 2003-04-22 | 2013-03-12 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| DE60321053D1 (de) | 2003-05-02 | 2008-06-26 | Polyphor Ag | Matrizenfixierte peptidmimetika als medikamente gegen hiv und krebs |
| WO2004096839A1 (en) | 2003-05-02 | 2004-11-11 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| WO2005002522A2 (en) | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
| EP1493438A1 (en) | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| ITMI20031754A1 (it) | 2003-09-12 | 2005-03-13 | Fabrizio Marcucci | Composizione microbicida. |
| US20050192272A1 (en) | 2003-12-22 | 2005-09-01 | Garland Marshall | Substituted benzodiazepines as inhibitors of the chemokine receptor CXCR4 |
| GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
| JP3977411B2 (ja) * | 2004-03-10 | 2007-09-19 | 株式会社クレハ | アミン系塩基性化合物とその用途 |
| US7776863B2 (en) | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
| US20050215544A1 (en) | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
| US20050215543A1 (en) | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
| CA2575560A1 (en) | 2004-08-02 | 2006-02-23 | Smithkline Beecham Corporation | Chemical compounds |
| AR050522A1 (es) | 2004-08-16 | 2006-11-01 | Smithkline Beecham Corp | Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv |
| JP5135795B2 (ja) * | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
| WO2006039252A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Compositions and methods for treating ophthalmic diseases |
| US20060265312A1 (en) | 2005-03-18 | 2006-11-23 | Spencer Rascoff | Online real estate auctions |
-
2006
- 2006-10-27 EP EP06822530.9A patent/EP1942108B1/en not_active Not-in-force
- 2006-10-27 PT PT68225309T patent/PT1942108E/pt unknown
- 2006-10-27 JP JP2007542710A patent/JP5251127B2/ja not_active Expired - Fee Related
- 2006-10-27 US US12/091,403 patent/US8318931B2/en not_active Expired - Fee Related
- 2006-10-27 EP EP13170147.6A patent/EP2657235A1/en not_active Withdrawn
- 2006-10-27 PL PL06822530T patent/PL1942108T3/pl unknown
- 2006-10-27 DK DK06822530.9T patent/DK1942108T3/da active
- 2006-10-27 WO PCT/JP2006/321569 patent/WO2007049771A1/ja not_active Ceased
- 2006-10-27 ES ES06822530T patent/ES2427989T3/es active Active
-
2012
- 2012-08-28 US US13/596,780 patent/US8614323B2/en not_active Expired - Fee Related
- 2012-11-12 JP JP2012248824A patent/JP2013032397A/ja not_active Withdrawn
-
2013
- 2013-11-08 US US14/075,538 patent/US8871210B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2007049771A1 (ja) | 2009-04-30 |
| US20090118279A1 (en) | 2009-05-07 |
| JP2013032397A (ja) | 2013-02-14 |
| US20120328627A1 (en) | 2012-12-27 |
| EP1942108B1 (en) | 2013-09-04 |
| JP5251127B2 (ja) | 2013-07-31 |
| DK1942108T3 (da) | 2013-12-09 |
| US8318931B2 (en) | 2012-11-27 |
| WO2007049771A1 (ja) | 2007-05-03 |
| US20140072576A1 (en) | 2014-03-13 |
| US8871210B2 (en) | 2014-10-28 |
| US8614323B2 (en) | 2013-12-24 |
| EP1942108A4 (en) | 2010-10-20 |
| PT1942108E (pt) | 2013-10-24 |
| EP1942108A1 (en) | 2008-07-09 |
| ES2427989T3 (es) | 2013-11-05 |
| EP2657235A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1790639A4 (en) | A BASIC GROUP CONNECTING AND APPLYING THEREOF | |
| EP1942108A4 (en) | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | |
| PL1961744T3 (pl) | Związek zawierający grupę zasadową oraz jego zastosowanie | |
| GB0512940D0 (en) | Compounds and their use | |
| IL185223A0 (en) | Compounds and uses thereof | |
| GB0520743D0 (en) | Compounds and their use | |
| EP1945258A4 (en) | FDT RELATED COMPOUNDS AND THEIR ANALOGUES | |
| IL192820A0 (en) | Novel compounds and use thereof | |
| GB0804899D0 (en) | Compound composition and use | |
| ZA200804378B (en) | Iminopropene compound and use thereof | |
| GB0427723D0 (en) | Compounds and their use | |
| GB0513176D0 (en) | Compounds and their use | |
| GB0521278D0 (en) | Compounds and their use | |
| GB0514416D0 (en) | Compounds and uses thereof | |
| GB0521272D0 (en) | Compounds and uses thereof | |
| GB0410832D0 (en) | Compounds and their use | |
| GB0405304D0 (en) | Compounds and their use | |
| GB0402903D0 (en) | Compounds and their use | |
| GB0410114D0 (en) | Compounds and their use | |
| GB0409377D0 (en) | Compounds and their use | |
| GB0401243D0 (en) | Compounds and their use | |
| GB0407628D0 (en) | Compounds and their use | |
| GB0403953D0 (en) | Compounds and their use | |
| GB0409378D0 (en) | Compounds and their use | |
| GB0410833D0 (en) | Compounds and their use |